CaSRevolution is a Milan-based virtual biotech developing first-in-class oral, brain-penetrant CaSR negative allosteric modulators (calcilytics) as a disease-modifying therapy for Alzheimer's. CaSR is an amplification hub linking amyloid production, neuroinflammation and synaptic dysfunction—the node anti-amyloid antibodies miss. The only company globally pursuing brain-penetrant calcilytics for AD, we are at the hit-to-lead stage with proprietary chemistry, raising a €5M seed extension.